GlassScriptPhysician profile
Trevor J Squire
NPI 1992978753
$112,314.82
in general payments reported to CMS, 2019-2025
17 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $14K · 2021: $17K · 2022: $33K · 2023: $8,950 · 2024: $11K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Consulting Fee: $1,525 · Travel and Lodging: $1,318 · Food and Beverage: $612 · Education: $50.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,895.00 |
| Consulting Fee | $1,525.00 |
| Travel and Lodging | $1,317.71 |
| Food and Beverage | $611.93 |
| Education | $50.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $38,918.12 | 2020-2025 | Kisunla |
| Teva Pharmaceuticals USA, INC. | $24,167.07 | 2021-2023 | Austedo Xr, Austedo |
| Sk Life Science, INC. | $23,873.45 | 2020-2023 | |
| Pfizer INC. | $14,196.58 | 2025 | |
| Acadia Pharmaceuticals INC | $10,229.18 | 2019 | |
| Livanova USA, INC. | $239.57 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Greenwich Biosciences, INC. | $169.81 | 2020-2021 | |
| Biogen, INC. | $150.00 | 2019 | |
| Dixi Medical USA Corp | $75.35 | 2023 | |
| Inspire Medical Systems, INC. | $63.65 | 2023 | Inspire |
| Ucb, INC. | $58.35 | 2023-2025 | Fintepla, Rystiggo |
| Novartis Pharmaceuticals Corporation | $53.09 | 2021-2022 | |
| Genzyme Corporation | $45.79 | 2021 | |
| Jazz Pharmaceuticals INC. | $25.79 | 2022 | |
| Argenx US, INC. | $18.61 | 2024 | Vyvgart Hytrulo |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $16.72 | 2024 | |
| Supernus Pharmaceuticals, INC. | $13.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trevor Squire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.